Arvinas Inc (NASDAQ:ARVN) Insider Sells $31,065.86 in Stock

Arvinas Inc (NASDAQ:ARVN) insider Ian Taylor sold 826 shares of the stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $37.61, for a total transaction of $31,065.86. Following the completion of the transaction, the insider now owns 71,224 shares in the company, valued at $2,678,734.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Shares of NASDAQ ARVN opened at $40.82 on Thursday. The firm has a fifty day moving average price of $46.71 and a 200-day moving average price of $36.47. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.86 and a quick ratio of 8.86. The stock has a market cap of $1.48 billion, a PE ratio of -19.35 and a beta of 2.44. Arvinas Inc has a 1 year low of $14.06 and a 1 year high of $54.95.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Monday, March 16th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.02). The firm had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $4.77 million. Arvinas had a negative return on equity of 30.16% and a negative net margin of 163.56%. On average, research analysts expect that Arvinas Inc will post -2.47 EPS for the current year.

Several research analysts have weighed in on ARVN shares. HC Wainwright started coverage on shares of Arvinas in a research report on Thursday, December 19th. They issued a “buy” rating and a $50.00 price target on the stock. BidaskClub downgraded shares of Arvinas from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 13th. Piper Jaffray Companies increased their price target on shares of Arvinas from $35.00 to $58.00 and gave the stock an “overweight” rating in a research report on Monday, January 6th. Zacks Investment Research raised shares of Arvinas from a “hold” rating to a “buy” rating and set a $37.00 price objective for the company in a research note on Tuesday, March 17th. Finally, Wedbush increased their price objective on shares of Arvinas from $39.00 to $60.00 and gave the stock an “outperform” rating in a research note on Friday, January 24th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Arvinas currently has an average rating of “Buy” and a consensus price target of $49.55.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Meeder Asset Management Inc. purchased a new stake in shares of Arvinas in the fourth quarter worth $48,000. Quantbot Technologies LP purchased a new position in Arvinas during the fourth quarter valued at $68,000. Tower Research Capital LLC TRC purchased a new position in Arvinas during the third quarter valued at $47,000. Bank of Montreal Can grew its stake in Arvinas by 66.3% during the fourth quarter. Bank of Montreal Can now owns 2,677 shares of the company’s stock valued at $110,000 after acquiring an additional 1,067 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in Arvinas during the fourth quarter valued at $165,000. 77.22% of the stock is owned by hedge funds and other institutional investors.

Arvinas Company Profile

Arvinas, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer.

Recommended Story: Why Invest in High-Yield Dividend Stocks?

Insider Buying and Selling by Quarter for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with's FREE daily email newsletter.